Athenex, Inc. (NASDAQ:ATNX) has earned an average broker rating score of 1.50 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company.

Brokerages have set a 1-year consensus price target of $27.50 for the company, according to Zacks. Zacks has also assigned Athenex an industry rank of 105 out of 265 based on the ratings given to its competitors.

A number of equities analysts have commented on the stock. Laidlaw assumed coverage on shares of Athenex in a research note on Tuesday, September 19th. They issued a “buy” rating and a $36.00 price objective for the company. Royal Bank Of Canada assumed coverage on shares of Athenex in a research note on Thursday, September 14th. They issued an “outperform” rating and a $35.00 price objective for the company. Credit Suisse Group assumed coverage on shares of Athenex in a research note on Monday, September 18th. They issued an “outperform” rating and a $25.00 price objective for the company. Finally, Deutsche Bank AG assumed coverage on shares of Athenex in a research note on Monday, July 10th. They set a “buy” rating and a $20.00 price target for the company.

Athenex (NASDAQ:ATNX) traded up 1.74% during mid-day trading on Wednesday, reaching $18.08. 198,786 shares of the company’s stock traded hands. Athenex has a 12-month low of $11.21 and a 12-month high of $20.79. The stock’s market capitalization is $1.03 billion. The stock has a 50-day moving average price of $17.01 and a 200-day moving average price of $16.64.

Athenex (NASDAQ:ATNX) last issued its quarterly earnings data on Monday, August 14th. The company reported ($0.88) EPS for the quarter. The business had revenue of $4.60 million for the quarter. Equities research analysts expect that Athenex will post ($2.22) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Zacks: Athenex, Inc. (ATNX) Receives Average Rating of “Buy” from Analysts” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/04/zacks-athenex-inc-atnx-receives-average-rating-of-buy-from-analysts.html.

Several hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. purchased a new position in shares of Athenex during the 2nd quarter worth about $601,000. Tudor Investment Corp ET AL purchased a new position in shares of Athenex during the 2nd quarter worth about $320,000. OxFORD Asset Management LLP purchased a new position in shares of Athenex during the 2nd quarter worth about $956,000. California Public Employees Retirement System purchased a new position in shares of Athenex during the 2nd quarter worth about $800,000. Finally, Vanguard Group Inc. purchased a new position in shares of Athenex during the 2nd quarter worth about $800,000. 0.88% of the stock is owned by hedge funds and other institutional investors.

Athenex Company Profile

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Get a free copy of the Zacks research report on Athenex (ATNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Athenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc. and related stocks with our FREE daily email newsletter.